Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2016—Bio-Rad Laboratories announced CE IVD marking for its QX200 Droplet Digital PCR System. The technology, which partitions a DNA or RNA sample into 20,000 droplets and amplifies targeted sequences within each droplet, allows scientists to precisely detect and quantify low concentrations of target DNA and RNA sequences.
April 2016—Euroimmun, headquartered in Luebeck, Germany, has developed a system of comprehensive tests available for the serological detection and differentiation of Zika virus infections.
April 2016—Swift Biosciences and SeraCare Life Sciences will partner to accelerate development of a novel circulating tumor DNA reference material.
April 2016—Mikroscan Technologies released the SL5, a real-time telepathology and whole slide imaging solution for use in anatomic pathology applications.
April 2016—Myriad Genetics announced a strategic research collaboration with Tesaro and Merck (known as MSD outside the U.S. and Canada) to help identify potential responders to an investigational combination drug therapy using Tesaro’s PARP inhibitor (niraparib) plus Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.
April 2016—Illumina has acquired Conexio Genomics, based in Fremantle, Western Australia.
April 2016—Boekel Scientific introduced its Heat Cool Thermal Mixer II, which features a large intuitive touchscreen, interchangeable auto-recognized blocks to fit most laboratory consumables, multiple modes for increased process performance, and a large and accurate temperature and mixing range.
April 2016—Streck’s A1c-Cellular is now assayed for the Ortho-Clinical Diagnostics Vitros 4600. A1c-Cellular is an HbA1c control with intact red blood cells and tests the entire HbA1c procedure, including the lysing of the red blood cell.
April 2016—Leica Biosystems and Advanced Cell Diagnostics announced a comprehensive partnership to develop and commercialize tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridization assays on Leica’s Bond clinical advanced staining instruments.
April 2016—LabStyle Innovations is preparing to launch its FDA-cleared Dario Blood Glucose Monitoring System in the United States.
